Navigation Links
GeoVax Labs Reports 2012 First Quarter Financial Results
Date:5/15/2012

of Health (NIH). This compares to $893,002 of grant revenue reported for the same period in 2011. As of March 31, 2012, there is approximately $3.3 million in unused IPCAVD grant funds available for use through August 31, 2012 (the end of the original project period).

Research and development (R&D) expenses were $1,072,354 for the three months ended March 31, 2012, compared with $838,467 for the comparable period in 2011. R&D expenses include direct costs funded by the IPCAVD grant, as well as vaccine manufacturing costs and expenses related to the Phase 1/2 clinical trial, being sponsored by GeoVax, of the Company's therapeutic HIV vaccine. Costs associated with the Phase 2a clinical trial of GeoVax's preventative HIV vaccine, being conducted by the HVTN, are being funded directly by the NIH and are therefore not reflected in GeoVax's financial statements. General and administrative (G&A) expenses were $512,818 and $661,813 for the three months ended March 31, 2012 and 2011, respectively.

GeoVax reported cash balances of $2,240,486 at March 31, 2012, as compared to $1,167,980 at December 31, 2011. Summarized financial information is attached. Further information concerning the Company's financial position and results of operations are included in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission.

About GeoVax's TechnologyGeoVax's unique two component vaccine, a recombinant DNA and a recombinant modified vaccinia Ankara (MVA), is designed to stimulate both anti-HIV T cell and anti-HIV antibody immune responses. GeoVax's DNA and MVA vaccines are used in a prime/boost protocol in which priming is done with the DNA and boosting with the MVA. Both the DNA and MVA express the three major proteins of the AIDS virus: Gag, Pol, and Env, and produce non-infectious virus-like-particles. GeoVax's vaccines are unique in expressing virus-like particles that display the trimeric membrane bound form of the HIV-
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. GeoVax Labs CEO Update Letter to Shareholders
2. GeoVax Labs First Patient Inoculated in Phase 1/2 Clinical Trial for HIV/AIDS Therapeutic Vaccine
3. GeoVax Phase 2a Clinical Trial Completes Enrollment
4. GeoVax $3.6 Million Award Increased to $4.4 Million by U.S. Government
5. GeoVax Labs, Inc. Announces Second Quarter Financial Results
6. GeoVax Labs HIV/AIDS Vaccine Development Leadership to be Highlighted During 2011 World Vaccine Congress
7. GeoVax Announces Publication of Phase 1 Clinical Trial in The Journal of Infectious Diseases
8. GeoVax Launches a Second Clinical Site to Test the Therapeutic Benefit of its HIV Vaccine
9. David A. Dodd Appointed Chairman of the Board of GeoVax Labs
10. GeoVax Announces Expansion of Phase 2a Human HIV/AIDS Vaccine Trial
11. GeoVax Awarded Federal Grant Under the Qualifying Therapeutic Discovery Project Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... SAN DIEGO and WALTHAM, Mass., July 29, ... LLP is investigating whether certain officers ... breached their fiduciary duties to shareholders.  AMAG Pharmaceuticals ... on maternal health, anemia, and cancer supportive care.  ... to reduce the risk of preterm birth in ...
(Date:7/29/2015)... July 29, 2015  Cryoport, Inc. (NASDAQ: ... the leading provider of advanced cryogenic logistics ... markets including immunotherapies, stem cells, cell lines, ... and reproductive medicine, announced today that the ... stock and warrants (the "Units") under a registered public ...
(Date:7/29/2015)... FRANCISCO , July 29, 2015   KaloBios ... antibody company focused on developing innovative therapies to benefit ... focus on oncology, announced today that the U.S. Food ... new drug (IND) application for KB003, an anti-GM-CSF monoclonal ... and that the IND is now active. ...
Breaking Medicine Technology:Robbins Arroyo LLP Is Investigating the Officers and Directors of AMAG Pharmaceuticals, Inc. (AMAG) on Behalf of Shareholders 2Cryoport Completes $6.8 Million Equity Capital Raise 2Cryoport Completes $6.8 Million Equity Capital Raise 3KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia 2KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia 3KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia 4KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia 5
... , PRINCETON, N.J., Nov. 9 Pharmasset, Inc. (Nasdaq: ... Lazard Capital Markets Healthcare Conference. The conference will be held ... 17-19, 2009). , Schaefer Price, Pharmasset,s President and Chief Executive ... November 18, 2009 at 3:45 PM (ET). , To access ...
... 9 Par Pharmaceutical Companies, Inc. (NYSE: PRX ... date and increased the purchase price of its previously ... is offering to purchase, for cash, up to $65,000,000 ... its outstanding 2.875% Senior Subordinated Convertible Notes due 2010. ...
Cached Medicine Technology:Pharmasset to Present at Lazard Capital Markets Healthcare Conference 2Pharmasset to Present at Lazard Capital Markets Healthcare Conference 3Par Pharmaceutical Announces Extension and Increase in Maximum Purchase Price for 'Modified Dutch Auction' Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Note 2Par Pharmaceutical Announces Extension and Increase in Maximum Purchase Price for 'Modified Dutch Auction' Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Note 3
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... ... success of musical artists to crowd-funding campaigns that give small businesses financial support, ... health solutions company and innovator in employee health management programs, unveiled today a ...
(Date:7/29/2015)... ... July 29, 2015 , ... Gender minority people ... 2012, Massachusetts law has provided legal protections against discrimination on the basis of ... not protect against discrimination based on gender identity in places open to the ...
(Date:7/29/2015)... Washington, DC (PRWEB) , ... July 29, 2015 , ... ... a company rebrand, changing its name to Rock the Reformer ® by Potomac Pilates. ... website - http://www.RockTheReformer.com . Rock the Reformer ® by Potomac Pilates will continue ...
(Date:7/29/2015)... ... July 29, 2015 , ... More than 28,000 students ... of children living with autism will converge upon Penn State to share the ... The National Autism Conference will be held Aug. 3-6 at the Penn Stater ...
(Date:7/29/2015)... ... July 29, 2015 , ... The NCCA re-accredited the ... expiring November 30, 2019, during its recent meeting. , The Commission received renewal ... program’s compliance with the NCCA’s Standards for the Accreditation of Certification Programs. ...
Breaking Medicine News(10 mins):Health News:StayWell Unveils Employer Guide to Developing Effective Employee Wellness Champion Networks 2Health News:StayWell Unveils Employer Guide to Developing Effective Employee Wellness Champion Networks 3Health News:StayWell Unveils Employer Guide to Developing Effective Employee Wellness Champion Networks 4Health News:Fenway Health Researcher: Legal Protections in Public Settings are a Critical Public Health Issue for Transgender and Gender-Nonconforming People 2Health News:Fenway Health Researcher: Legal Protections in Public Settings are a Critical Public Health Issue for Transgender and Gender-Nonconforming People 3Health News:Same Great Pilates Studio, New Brand - Rock the Reformer 2Health News:Penn State Conference to Address Instruction, Success for Children with Autism 2Health News:Commission for Case Manager Certification Receives Re-Accreditation of its CCM® credential from the National Commission for Certifying Agencies (NCCA) 2Health News:Commission for Case Manager Certification Receives Re-Accreditation of its CCM® credential from the National Commission for Certifying Agencies (NCCA) 3
... , , BASKING RIDGE, N.J., Sept. ... the development of antithrombotic therapeutic aptamers with active control ... the first patient in a Phase 2b, randomized, partially-blinded, ... the REG1 anticoagulation system (REG1) was achieved. REG1 ...
... TARRYTOWN, N.Y., Sept. 9 Bayer Diabetes Care today ... glucose meters -- Pink and Purple. , , ... to use(1) features as the original silver BREEZE2 meter, such as ... so users do not have to handle individual strips every time ...
... to develop PAD if they had constellation of other ... News) -- Women with metabolic syndrome are at high ... dramatically raises the risk of heart disease and stroke. ... taking part in the Women,s Health Study, researchers identified ...
... ... Staffing and Scheduling Earned the Highest Score Based on Direct Product Evaluations and In-depth, ... ... 9, 2009 -- Today at the Nursing Management Congress2009, RES-Q® Healthcare Systems announced that ...
... , WALTHAM, Mass., Sept. 9 ... research and advisory firms focusing on pharmaceutical and healthcare issues, ... messages among the ten surveyed osteoporosis brands likely as a ... commonly recalled that Sally Field promoted the brand or that ...
... , , ATLANTA, ... may have ended, but financial incentives for improving health and appearance ... Surgical Associates, "Cash for Crow,s Feet" program offers a ... at half the typical cost, said Dr. David R. Fern, FACS. ...
Cached Medicine News:Health News:Regado Biosciences Announces First Patient Enrolled in RADAR (Phase 2b) Study of REG1 Anticoagulation System 2Health News:Regado Biosciences Announces First Patient Enrolled in RADAR (Phase 2b) Study of REG1 Anticoagulation System 3Health News:Bayer's BREEZE(R)2 Meter Available in Two New Vibrant Colors for a Limited Time 2Health News:Metabolic Syndrome May Raise Risk of Peripheral Artery Disease 2Health News:RES-Q Labor Resource Management Ranked as the Top Staff Scheduling System Solution in KLAS 2009 Special Report 2Health News:Both Patients and Physicians Most Frequently Recall Roche's Boniva Messages and Link Them to the Sally Field Osteoporosis Campaign 2Health News:Both Patients and Physicians Most Frequently Recall Roche's Boniva Messages and Link Them to the Sally Field Osteoporosis Campaign 3Health News:'Cash For Crow's Feet' Program Offers Effective - and Affordable - Laser Skin Treatments 2
... Examination Tables deliver the highest quality care to ... types of patients can face a frustrating dilemma ... the exam table. Being able to easily get ... comfort during the exam, help the physician conduct ...
... This site introduces the DiamondTome™ ... with its unique DiamondTome™ Wands, an ... better way to smoother, more youthful ... we present the benefits of DiamondTome's™ ...
... Expand your practice with the advantages of ... effective treatment of leg veins and other deeper ... and fast. As a stand alone device or ... the Quantum DL treats a range of conditions ...
Inquire...
Medicine Products: